The All India Institute of Medical Sciences (AIIMS) in Delhi will begin screening children for clinical trials of an indigenous home-grown COVID-19 vaccine, Bharat Biotech’s Covaxin, on Monday (June 7, 2021), according to sources.
This news comes just one day after AIIMS Patna began paediatric trials for Covaxin on children aged 12 to 18.
On May 11, the Drugs Controller General of India (DCGI) approved Bharat Biotech to conduct clinical trials on children. DCGI approval was followed by a Subject Expert Committee recommendation on May 12 to grant trial permission (SEC).
Previously, VK Paul, a Niti Aayog member (Health), stated that “Covaxin has been approved by the Drugs Controller General of India (DCGI) for Phase II/III clinical trials in the age group of 2 to 18 years.”
Currently, India has three COVID-19 vaccines on the market: Bharat Biotech’s Covaxin, Serum Institute’s Covishield, and Russia’s Sputnik V.
Covaxin is an indigenously developed vaccine being used in adults in the ongoing COVID-19 vaccination drive by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Meanwhile, according to data from the Ministry of Health and Family Welfare, India saw its lowest single-day increase in COVID-19 cases in two months on Sunday, with 1.14 lakh new infections.
India’s active caseload has dropped by 77,449 in the last 24 hours, to 14,77,799.